Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

TEVA Stock Alert: What to Know as Teva Therapeutics' Scores FDA Approval for Schizophrenia Treament

Teva Pharmaceutical (TEVA) shares remain in focus after the company secured U.S. Food and Drug Administration (FDA) approval for Weltruza as a treatment for schizophrenia in adults. Teva expects availability in the coming weeks, with no loading doses, supplemental oral treatment, or post-injection monitoring required.

Including the post-announcement rally, TEVA stock is up about 30% versus the start of this year.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.